home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Plant Health Care signs agreement with Legacy Seeds for the development of a combination Myconate and Harpin product on alfalfa seeds in the USA


USA
July 2, 2010

Plant Health Care, a leading provider of naturally derived products to the agricultural and landscape industries, has entered into an agreement with one of the major alfalfa industry companies, Legacy Seeds, Inc. for the development of a combination Myconate and Harpin product on alfalfa seeds in the United States.

Under the four-year agreement, Plant Health Care will grant Legacy the exclusive rights to develop and market the Myconate and Harpin combination seed treatment technologies for use on alfalfa, the animal feed crop which is currently grown on more than 30 million acres in the US. In addition to supply payments, Plant Health Care will receive milestone payments under the terms of the agreement, which may be extended beyond the original four-year term.

With more than 60 years of combined seed industry experience, Legacy Seeds is one of the US’s major full-service seed companies specializing in clover, alfalfa and small grass seed with operations in Nampa, Idaho, and Waupaca, Wisconsin. They also service numerous independent seed companies who market under their own brands.

Bruce Ceranske, Vice President and Co-Founder at Legacy Seeds, said, “This is an exciting opportunity to bring two complementary, value-adding technologies to alfalfa growers. The early results from Plant Health Care look promising. If Myconate stimulates root development and Harpin increases vigor as they have in other major crops, then alfalfa growers stand to win on all counts and Legacy Seeds secures a valuable differentiation tool for our seeds.”

John Brady, CEO of Plant Health Care, commented, “This agreement represents a significant step forward for our company on several fronts. Legacy will be the first company to develop the power of both a Myconate and Harpin combined product for seed treatment on a very substantial crop. Alfalfa is one of the most important crops in the US and is planted on a very diverse range of soil and climatic conditions, which will further validate the flexibility and comprehensiveness of our product portfolio. Additionally, this deal along with our previously announced transactions demonstrates market appetite for Plant Health Care’s naturally derived technologies and underlines the value we put on partnering with industry leaders in order to derive maximum benefit from the technologies and value for our shareholders.”

Plant Health Care plc (“PHC”) is a leading provider of naturally derived products for plants and soil. Established in 1995 in Pittsburgh, Pennsylvania, PHC currently has approximately 90 employees and has operations in the United States, Mexico, the United Kingdom, Spain and the Netherlands. The Company’s ordinary shares have been quoted on the Alternative Investment Market (“AIM”) of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange (“CISX”) in February 2010 (ticker symbol/mnemonic: PHC).

PHC’s products are aimed at the agriculture and landscape industries and are environmentally beneficial. Through the commercialization of these products, PHC is capitalizing on current long-term trends toward natural systems and biological products for plant care and soil and water management. For more information, go to www.planthealthcare.com.
 



More news from:
    . Plant Health Care Plc
    . Legacy Seeds, Inc.


Website: http://www.planthealthcare.co.uk

Published: July 2, 2010

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section

 


Copyright @ 1992-2024 SeedQuest - All rights reserved